At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 50 target
Drug / intervention
ZG005 for Injection +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating ZG005 for Injection and Gecacitinib Hydrochloride Tablets for Non-small Cell Lung Cancer. Currently recruiting, targeting 50 participants across 1 site.
Detailed Summary
This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20262027
First PostedMar 2025
Enrollment StartMay 2025
TodayJul 2026
Primary CompletionApr 2027
Study CompletionMay 2027
First PostedMar 30, 2025
Enrollment StartMay 23, 2025
Primary CompletionApr 1, 2027
Study CompletionMay 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.3 years agoPrimary completion in 9 months
Interventions
ZG005 for Injectionbiological
intravenous infusion
Gecacitinib Hydrochloride Tabletsdrug
Oral